The Perspective on Secondary Research Practices: A Cross-Sectional Analysis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Data Collection and Research Method
2.3. Informed Consent Statement
2.4. Sample Characteristics
2.5. Survey Administration
2.6. Statistical Methods
3. Results
3.1. Study Group Characteristics
3.2. Descriptive Survey Results (Section II and Section III)
3.3. Statistical Analysis
4. Discussion
5. Limitations
6. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sackett, D.L.; Rosenberg, W.M.C.; Gray, J.A.M.; Haynes, R.B.; Richardson, W.S. Evidence Based Medicine: What It Is and What It Isn’t. 1996. Clin. Orthop. Relat. Res. 2007, 455, 3–5. [Google Scholar] [PubMed]
- Beecher, H.K. The Powerful Placebo. J. Am. Med. Assoc. 1955, 159, 1602–1606. [Google Scholar] [CrossRef] [PubMed]
- Bastian, H.; Glasziou, P.; Chalmers, I. Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up? PLoS Med. 2010, 7, e1000326. [Google Scholar] [CrossRef]
- Cipriani, A.; Furukawa, T.A.; Barbui, C. What Is a Cochrane Review? Epidemiol. Psychiatr. Sci. 2011, 20, 231–233. [Google Scholar] [CrossRef]
- Higgins, J.P.T.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A. (Eds.) Cochrane Handbook for Systematic Reviews of Interventions, 2nd ed.; John Wiley & Sons: Chichester, UK, 2019. [Google Scholar]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. Syst. Rev. 2021, 10, 89. [Google Scholar] [CrossRef]
- Bae, J.-M. Meta-Epidemiology. Epidemiol. Health 2014, 36, e2014019. [Google Scholar] [CrossRef]
- Sharma, A.; Minh Duc, N.T.; Luu Lam Thang, T.; Nam, N.H.; Ng, S.J.; Abbas, K.S.; Huy, N.T.; Marušić, A.; Paul, C.L.; Kwok, J.; et al. A Consensus-Based Checklist for Reporting of Survey Studies (CROSS). J. Gen. Intern. Med. 2021, 36, 3179–3187. [Google Scholar] [CrossRef]
- About—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/about/ (accessed on 2 July 2024).
- Mao, Y.; Lu, Z. MeSH Now: Automatic MeSH Indexing at PubMed Scale via Learning to Rank. J. Biomed. Semant. 2017, 8, 15. [Google Scholar] [CrossRef]
- Medical Subject Headings—Home Page. Available online: https://www.nlm.nih.gov/mesh/meshhome.html (accessed on 4 July 2024).
- Moons, P.; Goossens, E.; Thompson, D.R. Rapid Reviews: The Pros and Cons of an Accelerated Review Process. Eur. J. Cardiovasc. Nurs. 2021, 20, 515–519. [Google Scholar] [CrossRef]
- Siddaway, A.P.; Wood, A.M.; Hedges, L.V. How to Do a Systematic Review: A Best Practice Guide for Conducting and Reporting Narrative Reviews, Meta-Analyses, and Meta-Syntheses. Annu. Rev. Psychol. 2019, 70, 747–770. [Google Scholar] [CrossRef]
- Peterson, J.; Pearce, P.F.; Ferguson, L.A.; Langford, C.A. Understanding Scoping Reviews: Definition, Purpose, and Process. J. Am. Assoc. Nurse Pract. 2017, 29, 12–16. [Google Scholar] [CrossRef] [PubMed]
- Munn, Z.; Peters, M.D.J.; Stern, C.; Tufanaru, C.; McArthur, A.; Aromataris, E. Systematic Review or Scoping Review? Guidance for Authors When Choosing between a Systematic or Scoping Review Approach. BMC Med. Res. Methodol. 2018, 18, 143. [Google Scholar] [CrossRef] [PubMed]
- Munn, Z.; Stern, C.; Aromataris, E.; Lockwood, C.; Jordan, Z. What Kind of Systematic Review Should I Conduct? A Proposed Typology and Guidance for Systematic Reviewers in the Medical and Health Sciences. BMC Med. Res. Methodol. 2018, 18, 5. [Google Scholar] [CrossRef] [PubMed]
- Aromataris, E.; Munn, Z. Joanna Briggs Institute Reviewer’s Manual; The Joanna Briggs Institute: Adelaide, Australia, 2017. [Google Scholar]
- Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. PRISMA Group Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009, 6, e1000097. [Google Scholar] [CrossRef]
- Johnson, E.E.; O’Keefe, H.; Sutton, A.; Marshall, C. The Systematic Review Toolbox: Keeping up to Date with Tools to Support Evidence Synthesis. Syst. Rev. 2022, 11, 258. [Google Scholar] [CrossRef]
- Haile, Z.T. Critical Appraisal Tools and Reporting Guidelines. J. Hum. Lact. 2022, 38, 21–27. [Google Scholar] [CrossRef]
- Hooijmans, C.R.; Rovers, M.M.; de Vries, R.B.M.; Leenaars, M.; Ritskes-Hoitinga, M.; Langendam, M.W. SYRCLE’s Risk of Bias Tool for Animal Studies. BMC Med. Res. Methodol. 2014, 14, 43. [Google Scholar] [CrossRef]
- Else, H. How a Torrent of COVID Science Changed Research Publishing—In Seven Charts. Nature 2020, 588, 553. [Google Scholar] [CrossRef]
- Drzymalla, E.; Yu, W.; Khoury, M.J.; Gwinn, M. COVID-19-Related Manuscripts: Lag from Preprint to Publication. BMC Res. Notes 2022, 15, 340. [Google Scholar] [CrossRef]
- Iacobucci, G. New Preprint Server Allows Earlier Sharing of Research Methods and Findings. BMJ 2019, 365, l4110. [Google Scholar] [CrossRef]
- Gustot, T. Quality and Reproducibility during the COVID-19 Pandemic. JHEP Rep. 2020, 2, 100141. [Google Scholar] [CrossRef]
- Kodvanj, I.; Homolak, J.; Virag, D.; Trkulja, V. Publishing of COVID-19 Preprints in Peer-Reviewed Journals, Preprinting Trends, Public Discussion and Quality Issues. Scientometrics 2022, 127, 1339–1352. [Google Scholar] [CrossRef]
Question | Answers | Result [%] |
---|---|---|
What is your age? (In years) (n = 78) | 20–29 | 11.5 |
30–39 | 33.3 | |
40–49 | 23.1 | |
50–59 | 16.7 | |
60–69 | 11.5 | |
70–79 | 2.6 | |
>80 | 1.3 | |
What is your gender? (n = 78) | Woman | 38.4 |
Man | 59.0 | |
Non-binary | 1.3 | |
I prefer not to answer | 1.3 | |
In which country do you work? (n = 78) | UK | 10.3 |
India | 10.3 | |
US | 9.0 | |
Iran | 7.7 | |
Australia | 6.4 | |
Canada | 6.4 | |
Indonesia | 5.1 | |
Brazil | 3.8 | |
Germany | 3.8 | |
Spain | 3.8 | |
Denmark | 2.6 | |
Ethiopia | 2.6 | |
Italy | 2.6 | |
Philippines | 2.6 | |
Sweden | 2.6 | |
Others | 20.4 | |
What is your current occupational position/title? (n = 78) | Professor | 25.6 |
Associate Professor | 17.9 | |
Researcher in academia/industry/non-academic organisations | 15.4 | |
Assistant Professor | 11.5 | |
Postdoc | 10.3 | |
Student | 6.4 | |
Clinician | 5.1 | |
Others | 7.8 | |
How experienced are you in the secondary studies field (in years)? (n = 78) | Less than a year | 3.8 |
1–5 years | 20.5 | |
5–10 years | 30.8 | |
>10 years | 44.9 |
Section | Question Number | Question | Answer | Result (%) |
---|---|---|---|---|
2 | 2 (n = 78) | Do you use literature management software? | Always | 61.1 |
Sometimes | 29.1 | |||
Never | 9.8 | |||
2 | 4 (n = 78) | Do you register the protocol for secondary studies? | Yes, always | 41.0 |
Sometimes | 48.7 | |||
No, never | 10.3 | |||
2 | 5 (n = 78) | Have you conducted a Cochrane review yet? | Yes | 16.7 |
No | 83.3 | |||
2 | 6 (n = 78) | Do you use tools for creating keyword series? | Yes | 26.9 |
No | 73.1 | |||
2 | 7 (n = 78) | Do you use software for a Systematic Review? | Yes | 60.3 |
No | 39.7 | |||
2 | 8 (n = 78) | Do you follow any guidelines when conducting a Systematic Review? | Yes | 94.9 |
No | 5.1 | |||
2 | 9 (n = 78) | Do you perform a Systematic Review of other (published) Systematic Reviews? | Yes | 41.0 |
No | 59.0 | |||
2 | 11 (n = 78) | Do you perform the GRADE assessment for your Systematic Review? | Yes | 42.3 |
No | 35.9 | |||
Sometimes | 21.8 | |||
2 | 12 (n = 78) | Are you an author of any published secondary study related to COVID-19? | Yes | 89.7 |
No | 10.3 | |||
3 | 4 (n = 70) | Did you publish your work as a preprint? | Yes | 32.9 |
No | 67.1 | |||
3 | 5 (n = 68) | What was the time (in months) between submission and publishing the COVID-19-related paper (papers)? (Please describe every study) (open question) | 1–3 | 32.3 |
4–6 | 32.3 | |||
7–9 | 16.2 | |||
10–12 | 14.7 | |||
>12 | 4.5 |
Section | Question Number | Question | Answer | Result (%) |
---|---|---|---|---|
2 | 1 (n = 78) | Which medical databases do you use during the development of Systematic Reviews? | PubMed | 94.9 |
Cochrane Library | 69.2 | |||
Scopus | 69.2 | |||
Embase | 65.4 | |||
Web of Science | 62.8 | |||
PubMed Central | 48.7 | |||
Science Direct | 39.7 | |||
PsychInfo | 23.1 | |||
Others | 16.7 | |||
2 | 2.1 (n = 78) | Choose the software which you use | EndNote | 67.1 |
Mendeley | 41.4 | |||
Zotero | 18.6 | |||
Covidence | 11.4 | |||
Others | 20.0 | |||
2 | 3 (n = 78) | Which types of secondary studies did you prepare in the past? | Systematic Review | 97.4 |
Scoping Review | 57.7 | |||
Rapid Review | 37.2 | |||
Qualitative Systematic Review | 29.5 | |||
Umbrella Review | 23.1 | |||
Evidence Map | 7.7 | |||
Meta-analysis | 3.8 | |||
Narrative review | 1.3 | |||
2 | 4.1 (n = 70) | On which websites do you upload the Systematic Review protocol? | PROSPERO | 71.4 |
Cochrane.org | 20.0 | |||
Osf.io | 20.0 | |||
Dataryad.org | 5.7 | |||
Others | 10.0 | |||
2 | 6.1 (n = 21) | Which tools do you use for creating keyword series? | MeSH | 100.0 |
Emtree | 19.0 | |||
CD-10 | 9.5 | |||
MedDRA | 4.8 | |||
Cumulated Index of Nursing and Allied Health Literature (CINAHL) | 4.8 | |||
2 | 7.1 (n = 48) | Which software for a Systematic Review do you use? | Rayyan | 39.6 |
Covidence | 37.5 | |||
RevMan | 16.7 | |||
SysRev | 12.5 | |||
DistillerSR | 10.4 | |||
SR-Accelerator | 10.4 | |||
Excel (Meta)/Google Sheets | 8.3 | |||
RobotReviewer | 8.3 | |||
EPPI-Reviewer Web | 6.2 | |||
JBI SUMARI | 4.2 | |||
PICOPortal | 4.2 | |||
Others | 12.5 | |||
3 | 1 (n = 70) | At which stage of the COVID-19 pandemic did you prepare a secondary study (studies)? | January 2020–June 2020 | 34.3 |
July 2020–December 2020 | 38.6 | |||
January 2021–June 2021 | 41.4 | |||
July 2021–December 2021 | 35.7 | |||
January 2022–June 2022 | 22.9 | |||
July 2022–December 2022 | 17.1 | |||
3 | 3 (n = 70) | Which type of evidence did you prefer to incorporate into your secondary study (studies) conducted during the COVID-19 pandemic (2020–2022)? | Randomised trials [Randomised controlled trials (RCTs)] | 72.9 |
Cohort studies | 60.0 | |||
Cross-sectional study | 50.0 | |||
Case–control study | 42.9 | |||
Systematic Reviews | 31.4 | |||
Non-randomised trials | 27.1 | |||
Case series or case studies | 18.6 | |||
Single-arm trials | 10 | |||
Modelling studies | 7.1 | |||
Other | 7.1 | |||
3 | 6 (n = 70) | Which publisher published your paper related to the COVID-19 subject? | Elsevier | 40.6 |
Biomed Central (BMC) | 30.4 | |||
Springer | 24.6 | |||
Wiley | 14.5 | |||
MDPI | 13.0 | |||
BMJ (BMJ Open, BMJ Journals) | 8.7 | |||
Nature | 8.7 | |||
Taylor & Francis | 5.8 | |||
Others | 20.3 |
Question | Question VERSUS Question (Section Number/Question Number) | Correlation | Possible Interpretation |
---|---|---|---|
Which types of secondary studies did you prepare in the past? | Scoping Review (II/3) vs. Experience (I/5) p = 0.00738 df = 3 Chi2 = 12.00221 | Conducted Scoping Reviews vs. secondary studies experience | With experience, the frequency of conducting Scoping Reviews increases |
Do you register the protocol for secondary studies? | Yes, always/Sometimes (II/4) vs. Systematic Review (II/3) p = 0.00387 df = 2 Chi2 = 11.11158 | Registering protocol vs. conducting Systematic Reviews | Respondents conducting Systematic Reviews often register their study protocols |
Yes, always/Sometimes (II/4) vs. Scoping Review (II/3) p = 0.01958 df = 2 Chi2 = 7.866348 | Registering protocol vs. conducting Systematic Reviews | Respondents conducting Scoping Reviews rarely register their study protocols | |
Do you use tools for creating keyword series? | Yes (II/6) vs. PubMed Central (II/1) p = 0.01486 df = 1 Chi2 = 5.932568 | Using keyword generation tools vs. using PubMed Central | Respondents using PubMed Central often utilise keyword generation tools |
Do you use software for Systematic Review? | Yes (II/7) vs. Systematic Review (II/3) p = 0.02964 df = 1 Chi2 = 4.730322 | Using dedicated software vs conducting Systematic Reviews | Respondents conducting Systematic Reviews often use dedicated software |
Which software for Systematic Review do you use? | Covidence (II/7.1) vs. Rapid Review (II/1) p = 0.00843 df = 1 Chi2 = 6.938953 | Using Covidence vs. conducting Rapid Reviews | Respondents conducting Rapid Reviews often use the Covidence software (https://www.covidence.org/) |
Covidence (II/7.1) vs. Yes (II/5) p = 0.01906 df = 1 Chi2 = 5.495800 | Using Covidence vs. conducting Cochrane Systematic Reviews | Respondents conducting Cochrane Systematic Reviews often use the Covidence software | |
Please indicate in which stage of the Systematic Review do you use the software? | Screening (II/7.2) vs. Rapid Review (II/3) p = 0.02400 df = 1 Chi2 = 5.094851 | Using software during screening vs. conducting Rapid Reviews | Respondents conducting Rapid Reviews often use software at the screening stage |
Do you follow any guidelines when conducting a Systematic Review? | Yes (II/8) vs. Systematic Review (II/3) p = 0.02390 df = 1 Chi2 = 5.101622 | Following guidelines vs. conducting Systematic Reviews | Respondents conducting Systematic Reviews often use guidelines |
Which guidelines do you follow? | PRISMA (II/8.1) vs. Systematic Review (II/3) p = 0.00000 df = 1 Chi2 = 36.49315 | Following PRISMA guidelines vs. conducting Systematic Reviews | Respondents conducting Systematic Reviews often use PRISMA guidelines |
PRISMA (II/8.1) vs. Yes, always/Sometimes (II/4) p = 0.00320 df = 2 Chi2 = 11.48858 | Following PRISMA guidelines vs. registering study protocols | Respondents registering study protocols often use PRISMA guidelines | |
Do you perform Systematic Reviews of other (published) Systematic Reviews? | Yes (II/9) vs. Scoping Review (II/3) p = 0.03446 df = 1 Chi2 = 4.471640 | Conducting Umbrella Reviews vs. conducting Scoping Reviews | Respondents experienced in Scoping Reviews often conduct Umbrella Reviews |
Yes (II/9) vs. Evidence Map (II/3) p = 0.00224 df = 1 Chi2 = 9.343750 | Conducting Umbrella Reviews vs. conducting Evidence Map | Respondents experienced in Evidence Maps often conduct Umbrella Reviews | |
Yes (II/9) vs. Yes (II/5) p = 0.00395 df = 1 Chi2 = 8.308696 | Conducting Umbrella Reviews vs. conducting Cochrane Systematic Reviews | Respondents conducting Cochrane Systematic Reviews often conduct Umbrella Reviews |
Question | Question VERSUS Question (Section Number/Question Number) | Correlation | Possible Interpretation |
---|---|---|---|
Which type of evidence did you prefer to incorporate into your secondary study (studies) conducted during the COVID-19 pandemic (2020–2022)? | Randomised trials (III/3) vs. Embase (II/1) p = 0.00360 df = 1 Chi2 = 8.476092 | Preference of randomised trials vs. using Embase | Respondents using the Embase database often use randomised trials |
Non-randomised trials (III/3) vs. Web of Science (II/1) p = 0.04826 df = 1 Chi2 = 3.900929 | Preference of non-randomised trials vs. using Web of Science | Respondents using the Web of Science database often use randomised trials | |
Case–control (III/3) vs. Scopus (II/1) p = 0.00841 df = 1 Chi2 = 6.944445 | Preference of case–control studies vs. using Scopus | Respondents using the Scopus database often use case–control studies | |
Cross-sectional (III/3) vs. PubMed (II/1) p = 0.00265 df = 1 Chi2 = 9.032258 | Preference of cross-sectional studies vs. using PubMed | Respondents using the PubMed database often use cross-sectional studies | |
Randomised trials (III/3) vs. Systematic Review (II/3) p = 0.01873 df = 1 Chi2 = 5.526316 | Preference of randomised trials vs. conducting Systematic Reviews | Respondents conducting Systematic Reviews often use randomised trials | |
Non-randomised trials (III/3) vs. No (II/5) p = 0.02601 df = 1 Chi2 = 4.955580 | Preference of non-randomised trials vs. conducting Cochrane Systematic Reviews | Respondents conducting Cochrane Systematic Reviews rarely use non-randomised trials |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ratajczak, P.; Oziewicz, K.; Sommer, I.; Kopciuch, D.; Paczkowska, A.; Zaprutko, T.; Kus, K. The Perspective on Secondary Research Practices: A Cross-Sectional Analysis. Healthcare 2025, 13, 927. https://doi.org/10.3390/healthcare13080927
Ratajczak P, Oziewicz K, Sommer I, Kopciuch D, Paczkowska A, Zaprutko T, Kus K. The Perspective on Secondary Research Practices: A Cross-Sectional Analysis. Healthcare. 2025; 13(8):927. https://doi.org/10.3390/healthcare13080927
Chicago/Turabian StyleRatajczak, Piotr, Katarzyna Oziewicz, Isolde Sommer, Dorota Kopciuch, Anna Paczkowska, Tomasz Zaprutko, and Krzysztof Kus. 2025. "The Perspective on Secondary Research Practices: A Cross-Sectional Analysis" Healthcare 13, no. 8: 927. https://doi.org/10.3390/healthcare13080927
APA StyleRatajczak, P., Oziewicz, K., Sommer, I., Kopciuch, D., Paczkowska, A., Zaprutko, T., & Kus, K. (2025). The Perspective on Secondary Research Practices: A Cross-Sectional Analysis. Healthcare, 13(8), 927. https://doi.org/10.3390/healthcare13080927